Evidence map›Paper›PMID 38907244›Full record

ArticleReproductive biology and endocrinology : RB&E2024

FMR1 allelic complexity in premutation carriers provides no evidence for a correlation with age at amenorrhea.

Bárbara Rodrigues, Vanessa Sousa, Carolyn M Yrigollen, Flora Tassone, Olatz Villate, Emily G Allen, Anne Glicksman, Nicole Tortora, Sarah L Nolin, António J A Nogueira and 1 more

Abstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Population-based FMR1 carrier screening among reproductive women.Journal of assisted reproduction and genetics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bárbara RodriguesMolecular Genetics Laboratory, Laboratory Genetics Service, Genetics and Pathology Clinic, Unidade Local de Saúde de Santo António (ULSSA), Porto, Portugal.ORCID http://orcid.org/0000-0003-4698-962X
Vanessa SousaMolecular Genetics Laboratory, Laboratory Genetics Service, Genetics and Pathology Clinic, Unidade Local de Saúde de Santo António (ULSSA), Porto, Portugal.ORCID http://orcid.org/0000-0002-5855-1863
Carolyn M YrigollenRaymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-2399-6176
Flora TassoneDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, Stockton Blvd, USA.ORCID http://orcid.org/0000-0002-6388-9180
Olatz VillatePediatric Oncology Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Biscay, Basque Country, Spain.ORCID http://orcid.org/0000-0002-5574-837X
Emily G AllenDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-0963-036X
Anne GlicksmanNew York State Institute for Basic Research in Developmental Disabilities, New York, NY, USA.
Nicole TortoraNew York State Institute for Basic Research in Developmental Disabilities, New York, NY, USA.
Sarah L NolinNew York State Institute for Basic Research in Developmental Disabilities, New York, NY, USA.ORCID http://orcid.org/0000-0001-5209-289X
António J A NogueiraCESAM - Center for Environmental and Marine Studies, Department of Biology, University of Aveiro, Aveiro, Portugal.ORCID http://orcid.org/0000-0001-7089-2508
Paula JorgeMolecular Genetics Laboratory, Laboratory Genetics Service, Genetics and Pathology Clinic, Unidade Local de Saúde de Santo António (ULSSA), Porto, Portugal. paulajorge.icbas@gmail.com.ORCID http://orcid.org/0000-0002-6507-222X

Funding

Fundação para a Ciência e a Tecnologia EXPL/BIA-REP/0423/2021Fundação para a Ciência e a Tecnologia SFRH/BD/136398/2018Fundação para a Ciência e a Tecnologia UIDP/50017/2020+UIDB/50017/2020
6 · The paper itself

Abstract

backgroundPremutations in the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene, defined as between 55 and 200 CGGs, have been implicated in fragile X-associated primary ovarian insufficiency (FXPOI). Only 20% of female premutation carriers develop early ovulatory dysfunction, the reason for this incomplete penetrance is unknown. This study validated the mathematical model in premutation alleles, after assigning each allele a score representing allelic complexity. Subsequently, allelic scores were used to investigate the impact of allele complexity on age at amenorrhea for 58 premutation cases (116 alleles) previously published.

methodsThe allelic score was determined using a formula previously described by our group. The impact of each allelic score on age at amenorrhea was analyzed using Pearson's test and a contour plot generated to visualize the effect.

resultsCorrelation of allelic score revealed two distinct complexity behaviors in premutation alleles. No significant correlation was observed between the allelic score of premutation alleles and age at amenorrhea. The same lack of significant correlation was observed regarding normal-sized alleles, despite a nearly significant trend.

conclusionsOur results suggest that the use of allelic scores combination have the potential to explain female infertility, namely the development of FXPOI, or ovarian dysfunction, despite the lack of correlation with age at amenorrhea. Such a finding is of great clinical significance for early identification of females at risk of ovulatory dysfunction, enhancement of fertility preservation techniques, and increasing the probability for a successful pregnancy in females with premutations. Additional investigation is necessary to validate this hypothesis.

Indexed as

AllelesAmenorrheaFragile X Messenger Ribonucleoprotein 1Primary Ovarian InsufficiencyAdolescentAdultAge FactorsFemaleFragile X SyndromeHeterozygoteHumansMutationYoung AdultFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1Age at amenorrheaAGG interspersion patternCGG repeatsFMR1 allelic complexityFMR1 gene premutationFragile X-associated primary ovarian insufficiency

Identifiers

PMID38907244
PMCPMC11191145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.